Hudock Inc. Buys Shares of 1,734 iShares Biotechnology ETF (NASDAQ:IBB)

Hudock Inc. bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the fourth quarter, Holdings Channel.com reports. The firm bought 1,734 shares of the financial services provider’s stock, valued at approximately $229,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth about $29,000. Highline Wealth Partners LLC bought a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth about $30,000. HHM Wealth Advisors LLC raised its position in shares of iShares Biotechnology ETF by 200.0% during the 4th quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock worth $30,000 after buying an additional 150 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth about $36,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $33,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

IBB stock opened at $135.47 on Thursday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The firm’s 50-day moving average is $135.88 and its two-hundred day moving average is $141.13.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.